Gland Pharma said revenue from its core markets of the US, Europe, Canada and Australia grew by 3 per cent to Rs 747.5 crore in the second quarter, as against Rs 722.5 crore in the corresponding period last fiscal
Can Lumino Industries IPO deliver long-term growth for high-risk investors?
Lumino Industries plans a ₹700 crore initial public offering to reduce debt and boost manufacturing capacity. The company expects to benefit from increased demand for